Effect of Empagliflozin on Ventricular Repolarization.
Status:
Recruiting
Trial end date:
2022-01-31
Target enrollment:
Participant gender:
Summary
The present project aims to investigate if the empagliflozin has an antiarrhythmic action.
Analyzing the T-wave heterogeneity index, a new electrocardiographic risk marker associated
with the prediction of cardiovascular risk, in diabetic patients and coronary artery disease,
the investigators will verify if empagliflozin is associated with a reduction in electrical
instability.